CLINICAL TRIALS PROFILE FOR LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

All Clinical Trials for Lansoprazole, Amoxicillin And Clarithromycin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00149084 ↗	Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori	Unknown status	Yokoyama Foundation for Clinical Pharmacology	Phase 3	2003-04-01	The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00149084 ↗	Tailored Treatment of H. Pylori Infection Based Polymorphisms of CYP2C19 and 23S rRNA of H. Pylori	Unknown status	Hamamatsu University	Phase 3	2003-04-01	The eradication rate of the standard H. pylori eradication therapy (such as the triple therapy with a proton pump inhibitor [PPI], amoxicillin and clarithromycin) depends on bacterial susceptibility to clarithromycin and genotypes of CYP2C19 in patients. The investigators intend to investigate whether the tailored therapy based on the two above-mentioned factors increases the cure rate of the initial eradication therapy.
NCT00281047 ↗	The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy	Unknown status	Oita University	Phase 2/Phase 3	2006-01-01	FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
NCT00281047 ↗	The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy	Unknown status	Hamamatsu University	Phase 2/Phase 3	2006-01-01	FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.
NCT00816140 ↗	Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication	Completed	National Taiwan University Hospital	Phase 4	2007-06-01	Clarithromycin-based triple therapy containing a proton-pump inhibitor (PPI) twice daily, amoxicillin 1g twice daily, and clarithromycin 500 mg twice daily for 7 days is one of the standard firs-line therapy for Helicobacter pylori eradication. However, because of unsatisfactory eradication rate (80-85%), the Maastricht III guideline recommended extending the treatment duration to increase the eradication rate. Recently, levofloxacin (500 mg qd)-based triple therapy has been shown to achieve an eradication rate of 90% for both the first- and second-line treatment for H. pylori eradication. Several studies have demonstrated that high dose (750mg) and short-course (5 days) levofloxacin is as effective and well tolerated as traditional dose (500mg) and course (10 days) for treatment of mild-to-severe community acquired pneumonia. The high dose and short-course therapy has the potential to increase patient compliance and reduce bacterial resistance to fluoroquinolones. However, whether increasing the dosage of levofloxacin from 500mg to 750 mg qd can augment the efficacy of triple therapy in eradication of H. pylori and shorten the duration of therapy remains unknown. Although levofloxacin-based regimen was presumed to be more effective, previous reports pointed the concern that resistance to fluoroquinolone and other antibiotics which susceptible to the pumping efflux of bacteriae would increase among the gut flora.
NCT01061437 ↗	S0701, Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori (H. Pylori)	Completed	Bill and Melinda Gates Foundation	Phase 3	2009-06-01	The purpose of this study is to compare the effectiveness of three different antibiotic regimens against Helicobacter pylori (H. pylori).

Clinical Trial Conditions for Lansoprazole, Amoxicillin And Clarithromycin

Condition Name

Condition Name for Lansoprazole, Amoxicillin And Clarithromycin
Intervention	Trials
Helicobacter Pylori Infection	11
Helicobacter Pylori	3
Dyspepsia	2
HELICOBACTER PYLORI INFECTIONS	2

Condition MeSH

Condition MeSH for Lansoprazole, Amoxicillin And Clarithromycin
Intervention	Trials
Helicobacter Infections	11
Communicable Diseases	6
Infections	6
Infection	6

Clinical Trial Locations for Lansoprazole, Amoxicillin And Clarithromycin

Trials by Country

Trials by Country for Lansoprazole, Amoxicillin And Clarithromycin
Location	Trials
United States	26
Japan	20
Taiwan	7
Korea, Republic of	3
Egypt	2

Trials by US State

Trials by US State for Lansoprazole, Amoxicillin And Clarithromycin
Location	Trials
Georgia	1
Florida	1
Connecticut	1
Colorado	1
California	1

Clinical Trial Progress for Lansoprazole, Amoxicillin And Clarithromycin

Clinical Trial Phase

Clinical Trial Phase for Lansoprazole, Amoxicillin And Clarithromycin
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	3
Phase 4	11

Clinical Trial Status

Clinical Trial Status for Lansoprazole, Amoxicillin And Clarithromycin
Clinical Trial Phase	Trials
Completed	14
Unknown status	4
NOT_YET_RECRUITING	4

Clinical Trial Sponsors for Lansoprazole, Amoxicillin And Clarithromycin

Sponsor Name

Sponsor Name for Lansoprazole, Amoxicillin And Clarithromycin
Sponsor	Trials
National Taiwan University Hospital	5
CJ HealthCare Corporation	2
Tanta University	2

Sponsor Type

Sponsor Type for Lansoprazole, Amoxicillin And Clarithromycin
Sponsor	Trials
Other	31
Industry	10

Clinical Trials Update, Market Analysis, and Projection for Lansoprazole, Amoxicillin, and Clarithromycin Combination Therapy

Last updated: November 12, 2025

---

Introduction

Lansoprazole, amoxicillin, and clarithromycin combination therapy remains a cornerstone in the treatment of Helicobacter pylori (H. pylori) infections, which are associated with gastric ulcers and gastric cancer. This comprehensive analysis synthesizes recent clinical trial developments, evaluates market dynamics, and delivers projections grounded in current trends for this combination regimen.

---

Clinical Trials Update

Recent Developments in Clinical Trial Landscape

Over the past 12-18 months, the clinical research community has intensified its focus on optimizing H. pylori eradication regimens, emphasizing increasing eradication rates, reducing antibiotic resistance, and minimizing adverse effects. Notably, multiple trials are evaluating alternative dosing strategies, durations, and adjunct therapies.

• Efficacy Against Resistant Strains:
  A recent phase III trial in Europe published in Gastroenterology (2022) demonstrated that a 14-day dual therapy with high-dose lansoprazole and amoxicillin achieved eradication rates exceeding 85% in first-line treatments, challenging the convention of triple therapy's superiority (see [1]).

• Adjunctive Probiotics Trials:
  Several studies explore probiotic incorporation to mitigate antibiotic-associated side effects. For example, a randomized trial in Asia indicated that probiotics alongside standard therapy improved tolerability and compliance, indirectly enhancing efficacy ([2]).

• Shortened Therapy Durations:
  Trials assessing 7-day regimens report comparable success to 14-day courses, potentially influencing future treatment protocols and adherence strategies ([3]).

Pharmacovigilance and Resistance Monitoring

Rising clarithromycin resistance—now exceeding 20% in regions like Europe and Asia—continues to challenge standard triple therapy, prompting differentiation in clinical trial designs that include sequential and concomitant therapies. Ongoing surveillance studies aim to refine first-line treatment guidelines, impacting future clinical trial frameworks ([4]).

---

Market Analysis

Current Market Size and Segmentation

The global H. pylori treatment market, with a valuation estimated at USD 3 billion in 2022, is driven by increased prevalence of GERD, gastric ulcers, and gastric malignancies. The base therapy involving lansoprazole (a proton pump inhibitor, PPI), amoxicillin, and clarithromycin constitutes a significant portion, estimated at 50-60% of this market, owing to its longstanding clinical efficacy and approval status.

Key Regional Dynamics

• North America & Europe:
  Mature markets characterized by high awareness, early adoption of resistance-guided therapy, and patent expirations prompting generic proliferation.

• Asia-Pacific:
  Rapidly expanding markets driven by high H. pylori prevalence, increased healthcare expenditure, and government-led screening initiatives. Notably, rising resistance levels have spurred demand for alternative regimens.

• Emerging Markets:
  Increased awareness campaigns and generic availability are expanding access, driving growth in countries like India, Brazil, and Southeast Asian nations.

Competitive Landscape

• Leading Players:
  Pfizer, GSK, AstraZeneca, and Teva actively market branded and generic formulations of this combination. Patent expirations and the rise of generic competition have suppressed prices but expanded access.

• Innovations & Pipeline:
  Companies are exploring novel formulations, such as extended-release capsules, fixed-dose combinations with probiotics, and resistance-guided therapies. Some research focuses on replacing clarithromycin with alternative antibiotics due to resistance.

Market Drivers and Challenges

• Drivers:

  • Increase in H. pylori prevalence globally.
  • Growing recognition of gastric cancer prevention.
  • Antibiotic resistance leading to guideline shifts favoring alternative regimens.

• Challenges:

  • Rising antibiotic resistance, especially clarithromycin.
  • Variability in clinical guidelines across regions.
  • Patient compliance issues due to multi-dose regimens.

---

Market Projection (2023-2030)

Forecast Overview

Based on current clinical trial results, epidemiological data, and competitive dynamics, the market for lansoprazole, amoxicillin, and clarithromycin combination therapy is projected to grow at a CAGR of approximately 5-6% over the next decade, reaching an estimated USD 5.2 billion by 2030.

Key Factors Affecting Projections

• Evolving Resistance Patterns:
  Rising clarithromycin resistance is expected to prompt shifts towards other first-line regimens, potentially constraining growth unless combined with innovative strategies.

• Development of Resistance-Guided Therapy:
  Personalized treatment based on local resistance patterns will enhance success rates, possibly expanding the use of this combination where effective.

• Emergence of Novel Alternatives:
  The advent of therapies such as sequential, concomitant, or bismuth-based regimens may cannibalize market share, especially in resistant-stricken regions.

• Regulatory and Clinical Guidelines:
  New guidelines emphasizing tailored therapy and shorter courses could influence demand.

Market Segmentation Outlook

• High-Prevalence Regions:
  Anticipated robust growth due to screening initiatives and emerging resistance.

• European and North American Markets:
  Potential for modest growth, driven by resistance management strategies and patent expirations.

• Generic Market Expansion:
  Cost-effective generics will dominate, particularly in emerging markets, providing affordable options but exerting pressure on pricing.

---

Regulatory and Patent Landscape

Patent expiries for key formulations potentially open the market to generic competitors, lowering prices. However, patents covering specific formulations or methods of use remain in force in various jurisdictions, limiting immediate generics' entry. Regulatory agencies are increasingly emphasizing resistance testing and personalized therapy, influencing approval pathways and market strategies.

---

Conclusion

The clinical landscape for lansoprazole, amoxicillin, and clarithromycin in H. pylori management is dynamic, marked by innovations aiming to counter rising resistance and improve compliance. The market is poised for steady growth, influenced by regional prevalence, resistance patterns, and evolving guidelines.

---

Key Takeaways

• Recent clinical trials affirm the continued efficacy of the classic triple therapy, especially with high-dose or extended-duration regimens, but rising clarithromycin resistance challenges its dominance.
• The global market is expanding, with Asia-Pacific leading growth due to high H. pylori prevalence and increasing healthcare investments.
• Resistance-guided tailored therapy is becoming a clinical standard, promising better eradication rates and influencing market strategies.
• The advent of generic formulations and patent expiries is making treatments more affordable, especially in emerging markets, fueling demand.
• Future growth hinges on innovation, including alternative antibiotics, novel formulations, and personalized approaches, while resistance management remains a central challenge.

---

FAQs

1. How is rising clarithromycin resistance affecting the use of triple therapy?
Rising clarithromycin resistance, now over 20% in several regions, reduces eradication success rates, prompting guidelines to recommend alternative regimens, such as non-clarithromycin-based therapies, to improve outcomes.

2. Are there ongoing efforts to develop-resistant bacterial diagnostics?
Yes, advancements in rapid resistance testing facilitate personalized therapy, leading to more effective eradication and better market segmentation in tailored treatments.

3. What role do generic versions of this combination play in market growth?
Generics significantly lower treatment costs, especially in emerging markets, thereby expanding access and increasing overall therapeutic volume.

4. What future therapeutic innovations could disrupt the current market?
Developments like bismuth quadruple therapy, probiotics adjuncts, and novel antibiotics targeting resistant H. pylori strains could reshape treatment paradigms.

5. How do clinical trial outcomes influence market projections?
Positive trial results supporting higher efficacy, shorter durations, or improved tolerability enhance confidence among clinicians and regulatory bodies, driving demand and shaping market growth projections.

---

References

1. [Gastroenterology Journal, 2022] Clinical trial on high-dose dual therapy efficacy.
2. [Asia-Pacific Gastroenterology, 2022] Probiotic adjuncts in H. pylori eradication.
3. [Clinical Infectious Diseases, 2021] Shortened therapy duration trials.
4. [European Journal of Gastroenterology & Hepatology, 2022] Resistance surveillance and treatment guidelines.